

BIOMED 2026

Company Presentation Abstract Submission

Company name: Starget Pharma

Website: www.stargetpharma.com

CEO name: Sigal Kalmanson Cusnir

Category: Biotech/Pharma

Session: "AI Pharma" Drug Discovery, Quantum Computing

Title: Lights will guide you: AI-driven radioligands in the darkness of cancer

Executive Summary / Investment Rationale

Starget's AI-driven cyclic peptide radioligand platform rapidly discovers novel drugs for metastatic cancer—co-optimizing peptide, linker, chelator, and isotope via a radioligand-specific-integrated global labs in Israel, Europe, and the US. Two 2026 clinical programs: first-in-class SSTR3 (Phase 1b, sarcoma/melanoma/NETs, US) and novel GRPR (FIH, breast/GIST/prostate, Australia). We are building the leading AI engine for next-generation RLTs in a booming market.

Core Technology

Four layers, one engine: backbone-cyclization chemistry for conformational control and superior druggability; AI modules across design, linker, chelator, and isotope co-optimization; an integrated radioligand-specific Lab-in-the-Loop (Israel, Europe, US) running high-throughput synthesis, radiolabeling, and in vivo PET/SPECT imaging; and a proprietary data layer of thousands of tested radioligands fueling continuous learning loops. Together they compress discovery from hit to first-in-human in 12–18 months.

Product Profile / Pipeline

Lead first-in-class SSTR3 RLT program entered FIH, advancing to Phase 1b at MDAnderson in a basket study (sarcoma, melanoma, and NETs). A novel best-in-class backbone-cyclic GRPR RLT, demonstrating superior tumor-to-organ ratios vs. Novartis NeoB RLT, advancing to FIH in Australia. Additional pipeline programs including CCK2R, GPC3, and undisclosed targets are demonstrating promising preclinical data. AI RLT Platform collaboration opportunities available.

Business Strategy

Leveraging our AI RLT platform and a pipeline across a broad range of cancers. Our business model combines direct asset commercialization with strategic licensing and collaborations with major pharma companies. Market appetite is validated: Novartis acquired Mariana (peptide RLT platform) for \$1.75B at preclinical; BMS licensed, Phase1 prostate RLT for \$350M upfront; Aktis Oncology IPO'd at ~\$1B+, early Phase 1.

What's Next?

Starget is advancing on all fronts: clinical data from SSTR3 Phase 1b and GRPR FIH; a new program to FIH in 2027; additional programs to IND; pharma platform collaborations; and 10× Lab-in-the-Loop scale-up. Led by an experienced hi-tech and biotech team (incl. ex-founder of Urogen Pharma), with Series A recently closed, Starget is planning a Series B to fuel this next phase